JOC The Journal of Organic Chemistry

Article

A 5+1 Protic Acid-Assisted aza-Pummerer Approach for Synthesis of 4-Chloropiperidines From Homoallylic Amines

Rene Ebule, Sagar Mudshinge, Michael H. Nantz, Mark S. Mashuta, Gerald B. Hammond, and Bo Xu

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.8b03162 • Publication Date (Web): 13 Feb 2019

Just Accepted

ACS Publications

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

A 5+1 Protic Acid-Assisted *aza*-Pummerer Approach for Synthesis of 4-Chloropiperidines From Homoallylic Amines

Rene Ebule,[a] Sagar Mudshinge,[a] Michael H. Nantz,[a]] Mark S. Mashuta,[a] Gerald B. Hammond,[a],* Bo Xu[b],*

[a] Department of Chemistry, University of Louisville, Louisville, Kentucky 40292, United States; [b] College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, 2999 North Renmin Lu, Shanghai, China

Supporting Information Placeholder

ABSTRACT: We report that HCl•DMPU induces the formation of (thiomethyl)methyl carbenium ion from DMSO under mild conditions. Homoallylic amines react with this electrophile to generate 4-chloropiperidines in good yields. The method applies to both aromatic and aliphatic amines. The use of HCl•DMPU as both non-nucleophilic base and chloride source constitutes an environmentally benign alternative for piperidine formation. The reaction has a broad substrate scope, and the conditions offer good chemical yields with high functional group tolerance and scalability.

Introduction

Functionalized piperidines are ubiquitous in natural products[1] and pharmaceuticals (Figure 1).[2] Despite an extensive literature on piperidine syntheses,[3] there are still demands for more efficient syntheses. The common strategies for the synthesis of piperidine skeletons involve intra-[4], and intermolecular[5] cyclization reactions, ring expansion processes[6] and reduction of pyridines.[7] Cycloaddition is the more effective approach, achieved either by a nucleophilic substitution process (Scheme 1a),[3c, 8] transition metal catalysis (Scheme 1b),[3a, b, 9] or an electrophile- or radical-induced cyclization (Scheme 1c).[10] The use of designed or protected substrates and expensive transition metals limit the application of some of these methods. Another important method for obtaining 4-substituted piperidines is through the aza-Prins cyclization method (Scheme 1e).[5a, 11] This method usually requires transition metal or Lewis acid catalysis.



Figure 1. Examples of piperidine-containing natural products and drug molecules.

In our search for applications of the newly formulated HCl•DMPU,[12] a highly concentrated, bench stable, readily prepared and easily dispensable anhydrous source of HCl, we observed the activation of DMSO. Activation of dimethyl sulfoxide by electrophiles[13] has been widely reported and has led to the application of DMSO as a viable synthon,[14] as noted by the increased use of DMSO as a one carbon source in the recent literature (Scheme 1d).[15] We describe herein application of our HCl•DMPU-mediated DMSO activation to prepare 4-chloropiperidines.



Scheme 1. Literature background.

Despite the tremendous progress made in alkene amino cyclization reactions,[4, 11i, 16] there are still limitations in the substrate scope for intramolecular construction of piperidines. We wanted to avoid the use of toxic formaldehyde as a one carbon synthon. To address these limitations, we surmised one possible solution would be to exploit the formation of (thiomethyl)methyl carbenium ion from DMSO[17] will be trapped by homoallylic amines (Scheme 1f).[18] The thiocarbenium ion generation could arise from a Pummerer fragmentation through the interaction of the sulfoxide with an electrophile. Such activations are common in activated high-molecular weight sulfoxides.[19] However, protic acid activation of DMSO is rare.[20] We envisioned that reaction of the thiocarbenium ion with a homoallylic amine might initiate an intramolecular cyclization to form a piperidine ring. Specifically, tandem electrophilic capture of the DMSO-derived (thiomethyl)methyl carbenium ion by the homoallylic amine followed by intramolecular reaction of the pendant vinyl system with subsequent counterion trapping of the resulting electrophilic center could afford access to 4-substituted piperidines. Such an approach would provide a nice compliment to current halo-piperidation techniques.[5a, 11a, 21]

Results and Discussion

We began our investigation using the homoallylic amine **1a**, HCl•DMPU (2.4 equiv) and DMSO (2.4 equiv) in DCE at 65 °C (Table 1). We were pleased to obtain the desired cyclized product **2a** in decent yield**.** A solvent screening indicated a better conversion in ethyl acetate (Table 1, entries 1-5). Reaction concentration played an essential role in improving conversion and limiting side product of methylthiolation. (Table 1, entries 6 and 7).

We also investigated other HCl sources. As expected, the lower concentration sources were sluggish (Table 1, entries 8, and 10) while the more concentrated sources gave appreciable conversions with lower desired product ratios thwarted by thiolated side products (Table 1, entries 9 and 11). Use of aqueous HCl gave a dismal outcome; however, the conversions with *in situ* generated HCl (Table 1, entries 13 and 14) proceeded with comparable selectivity to the ready-made HCl•DMPU reagent. Encouraged by these results, we examined the substrate scope of this new cyclization reaction with the optimum condition in hand (**Table 2**).

Table 1. Reaction optimization.[a]



1a, 0.4 mmol — **2a**

Entry	Solvent	HCl source	Conc.	Conv. /%[a]
1	DCE	HCl•DMPU	1.0	64
2	CH_3CN	HCl•DMPU	1.0	22
3	CH_3NO_3	HCl•DMPU	1.0	30
4	EtOAc	HCl•DMPU	1.0	90
5	DMSO	HCl•DMPU	1.0	18
6	EtOAc	HCl•DMPU	0.5	89
7	**EtOAc**	**HCl•DMPU**	0.2	**99**
8	EtOAc	HCl, Et_2O	0.2	32 (98)[b]
9	EtOAc	HCl, 2-propanol	0.2	99[c]
10	EtOAc	HCl, dioxane	0.2	65 (94)[b]
11	EtOAc	HCl, AcOH	0.2	99[c]
12	EtOAc	HCl, H_2O	0.2	29 (65)[b]
13	EtOAc	CH_3COCl/EtOH	0.2	99
14	EtOAc	TMSCl/MeOH	0.2	95

[a]Determined by GC-MS with dodecane as the internal standard. [b] 24 h, [c] combined with thiolated side product.

Table 2. Substrate scope for the synthesis of 4-chloropiperidines.[a]



[a] **1** (0.2 mmol), HCl•DMPU (2.4 equiv), DMSO (2.4 equiv), 65 °C, 9-24 h. All yields are isolated yields.



Figure 2. Failed substrates.



Figure 3. ORTEP representation of (2n) with thermal ellipsoids shown at the 50% probability level.

We first examined the scope of homoallylic anilines. The study revealed that there was broad tolerance of substituents with various electronic properties on all positions on the aromatic ring giving good to excellent yields. An array of para-substituted anilines containing groups such as methyl (**2b**), halo (**2d, 2e, 2f**), trifluoromethyl (**2j**), methoxy (**2k**), cyano (**2l**), trifluoromethoxy (**2m**), nitro (**2n**), phenyl (**2r**) and acetyl (**2t**) all proceeded in excellent yields. Single crystal X-ray structure of the 4-nitrophenyl derivative (**2n**), was obtained showing the chlorine atom locked in the axial position (Figure 3). The inclusion of similar substituents at the ortho (**2i, 2o, 2s**) and meta (**2c, 2g, 2h, 2q**) positions did not affect the yields. The method displayed good functional group tolerance to groups like nitrile (**2l**), ester (**2w**), ethers (**2k, 2m, 2v**) and ketones (**2t, 2u**). Interestingly, homoallylic sulfonamides (**2aa, 2ab, 2ac**) transformed excellent yields. Heteroaromatic amines that contain benzodioxole (**2v**), thiophene (**2w**), pyridine (**2x, 2y**) and pyrazine (**2z**) moieties also gave desired cyclization products in good yields. While meta-polysubstitution (**2p**) was highly selective resulting in a yield of 90%, the trisubstituted substrate (**2ai**) gave an inseparable 3:2 mixture of piperidine and pyrrolidine respectively. Unfortunately, the method was unsuccessful with the hydrazide (**2aj**), hydroxylamine (**2ak**) and indole (**2al**) substrates likely due to substrate intolerance and product instability (Figure 2). We also examined aliphatic amines too. Though strongly basic, we were delighted to observe satisfactory product yields of 51-64%. The reaction conditions tolerated benzyl (**2ag, 2ah**) and longer aliphatic chain (**2ad, 2ae, 2af**) substrates.

Next, we investigated the scope of the alkene chain. Both terminal and internal substituted alkenes afforded desired products (Table 3). The disubstituted alkenes (**3a, 3b, 3c, 3d**) furnished the desired cyclized products (**4a, 4b, 4c, 4d**) in good yields of 81%, 84%, 53% and 65% respectively. The major diastereomer, **4d**, exhibited an anti-stereochemistry. The sterically hindered homoallylic amine derivative of nopol (**3c**) underwent the cyclization in a modest 53% yield. Due to steric demands, the 1,1,2-trisubstituted alkene substrate (**3e**) failed to achieve the desired outcomes. Rather it formed the kinetically

favored pyrrolidine product in 64% yield. The mass obtained by GCMS was consistent with that of the pyrrolidine product. Also, the cyclic alkene substrate (**3f**) was unsuccessful probably due to ring strain barrier associated with its formation.

Table 3. Scope for the synthesis of 4-chloropiperidines.[a]



3 **4**

entry	3	4	Yield[a]
1			**4a**, 81%
2			**4b**, 84%
3			**4c**, 53%
4			**4d,** 65%, 3:1 dr
5			**4e**, 64%[b]
6			**4f**, unsuccessful

[a] **3** (0.2 mmol), HCl·DMPU (2.4 equiv), DMSO (2.4 equiv), 65 °C, 9-18 h, isolated yields, [b] ^{1}H NMR with CH_2Br_2 as internal standard.

To demonstrate the practicality of the method, we conducted a ten mmol reaction (**Scheme 2,** eq 1) of **1a** without any further modifications and obtained the desired product **2a** in high yield. To probe the mechanism of the reaction, we carried a deuterium labeling experiment using deuterated DMSO. We observed high deuterium incorporation of over 99% for the resulting piperidine (**Scheme 2,** eq 2). This result indicates that the extra carbon arises from DMSO. During the preparation of this manuscript, Zhong and co-workers[22] reported that DMSO could serve as a formaldehyde surrogate. Using paraformaldehyde in place of DMSO under similar reaction conditions as ours also yielded the 4-chloropiperidine product (**Scheme 2,** eq 4). It is, however, inconclusive if that is the only operating mechanism because as earlier referenced, DMSO can equally serve as a one-carbon source. Given the abundance of chloride ion during the reaction, the *in-situ* generation of chloromethyl methyl sulfide (**IIb**) as an intermediate is possible. Indeed, the reaction of the starting amine with commercially available chloromethyl methyl sulfide led to the formation of **2a** in 64% yield (**Scheme 2,** eq 3). Finally, to seek insight as to the intermediary of an iminium ion before cyclization, we performed the reaction with tertiary amine **7** and observed no cyclization to give **2a**. Instead, the reaction gave the chlorothiolated product **8**[23] was formed in 67% (**Scheme 2,** eq 4).



Scheme 2. Gram scale reaction and mechanistic study.

Based on the above results, a plausible mechanism is proposed (**Scheme 3**). Electrophilic activation of DMSO by HCl generates sulfonium salt **I**, which undergoes base-assisted elimination of water to produce (thiomethyl)methyl carbenium ion **IIa**. Interchangeable formation of chloromethyl methyl sulfide (**IIb**) may also be operative. **IIa**/**b** reacts with the starting amine to ultimately generate iminium ion **V** from ammonium salt **IV** via proton transfer (P.T.) and elimination of methyl mercaptan. A 6-endo-trig cyclization[24] followed by nucleophilic addition of chloride ion gives the desired product.



Scheme 3. Proposed mechanism.

Conclusion

In summary, we have developed a convenient protic acid-catalyzed formation of (thiomethyl)methyl carbenium ion from DMSO under mild conditions. In the presence of homoallylic amines, the *in situ*-generated species reacts in aza-Pummerer fashion to generate an iminium ion intermediate that cyclizes to form 4-chloropiperidines in good yield. The method applies to both aromatic and aliphatic amines. The use of HCl•DMPU as protic acid, non-nucleophilic base and chloride source provides an environmentally benign process for piperidine formation. The reaction has a broad substrate scope and is scalable.

Experimental Section

1. General

^{1}H and ^{13}C (^{1}H) decoupled NMR spectra were recorded either at 400 MHz or 500 MHz, and 101 MHz using $CDCl_3$ or CD_2Cl_2 as a solvent. The chemical shifts are reported in δ (ppm) values (^{1}H and ^{13}C NMR relative to $CHCl_3$, δ 7.26 ppm for ^{1}H NMR and δ 77.0 ppm for ^{13}C NMR, multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), h (hextet), m (multiplet) and br (broad). Coupling constants (*J*), are reported in Hertz (Hz). The HRMS data was obtained from an Agilent Technologies QTOF spectrometer. All reagents and solvents were employed without further purification. The products were purified using a commercial flash chromatography system. TLC was developed on silica gel 60 F254 aluminum sheets.

2. General procedures

2.1 Procedure for generation of HCl/DMPU

The reagent HCl•DMPU was prepared as reported in the literature.[12a, b]

2.2 General procedure for the preparation of homoallylic amines, 1 and 3[25].

To a round-bottomed flask equipped with a stirring bar was charged with aryl or alkylamine **1 or 3** (1.2 mmol, 1.2 equiv), K_2CO_3 (2 mmol, 2 equiv) and dry DMF (3 mL). Homoallyl bromide (1 mmol, 1 equiv) was slowly added to the mixture and heated to 110 °C. We monitored the progress of the reaction by GC-MS or TLC. Upon completion, the reaction mixture was cooled to room temperature and water (10 mL) and extracted with ethyl acetate (3 X 10 mL). The combined organic layers were then dried over anhydrous Na_2SO_4, filtered, concentrated and eventually purified silica gel column chromatography with hexanes/ethyl acetate (typically 70/30) or petroleum ether/ethyl acetate (80/20 for **1v**, **1x**, **1y**, **1af**, **1ag**, and **3c**) as eluent.

N-(but-3-en-1-yl)aniline **(1a)** Light yellow oil, 89.8 mg, 61% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.19 (t, *J* = 7.9 Hz, 2H), 6.72 (t, *J* = 7.3 Hz, 1H), 6.63 (d, *J* = 7.8 Hz, 2H), 5.85– 5.79 (m, 1H), 5.21 – 5.07 (m, 2H), 3.63 (s, 1H), 3.20 (t, *J* = 6.7 Hz, 2H), 2.40 (q, *J* = 6.7 Hz, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 148.4, 136.0, 129.4, 117.6, 117.3, 113.1, 43.0, 33.8.

N-(but-3-en-1-yl)-4-methylaniline **(1b)** Colorless oil, 103.2 mg, 64% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.00 (d, *J* = 8.0 Hz, 2H), 6.56 (d, *J* = 8.0 Hz, 2H), 5.87– 5.78 (m, 1H), 5.17 – 5.10 (m, 2H), 3.52 (s, 1H), 3.17 (t, *J* = 6.7 Hz, 2H), 2.38 (q, *J* = 6.7 Hz, 2H), 2.25 (s, 3H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ = 146.1, 136.0, 129.8, 126.7, 117.1, 113.2, 43.3, 33.8, 20.5.

N-(but-3-en-1-yl)-3-methylaniline **(1c)** Colorless oil, 109.8 mg, 68% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.07 (t, *J* = 7.9 Hz, 1H), 6.53 (d, *J* = 7.6 Hz, 1H), 6.43 (d, *J* = 7.7 Hz, 2H), 5.86 – 5.78 (m, 1H), 5.17 – 5.10 (m, 2H), 3.60 (s, 1H), 3.18 (t, *J* = 6.7 Hz, 2H), 2.42 – 2.32 (m, 2H), 2.28 (s, 3H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 148.2, 138.9, 135.7, 129.0, 118.2, 116.9, 113.6, 109.9, 42.7, 33.6, 21.5.

N-(but-3-en-1-yl)-4-fluoroaniline **(1d)** Colorless oil, 94.1 mg, 57% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 6.88 (t, *J* = 8.8 Hz, 2H), 6.54 (dd, *J* = 9.0, 4.4 Hz, 2H), 5.85 – 5.76 (m, 1H), 5.17 – 5.10 (m, 2H), 3.54 (s, 1H), 3.14 (t, *J* = 6.7 Hz, 2H), 2.37 (q, *J* = 6.7 Hz, 2H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 156.8, 144.6, 135.7, 117.2, 115.7, 115.6, 113.7, 43.5, 33.6. **^{19}F NMR (376 MHz, $CDCl_3$)** δ -128.35.

N-(but-3-en-1-yl)-4-chloroaniline **(1e)** Colorless oil, 116.2 mg, 63% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 7.11(d, *J* = 7.8, 2H), 6.53 (d, *J* = 7.9, 2H), 5.81 – 5.77 (m, 1H), 5.15 – 5.10 (m, 2H), 3.66 (s, 1H), 3.14 (t, *J* = 6.4 Hz, 2H), 2.37 (q, *J* = 6.7, 2H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 146.8, 135.5, 129.0, 121.9, 117.3, 113.9, 42.9, 33.5.

4-bromo-N-(but-3-en-1-yl)aniline **(1f)** Colorless oil, 146.9 mg, 65% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.36 (d, *J* = 8.8 Hz, 2H), 6.60 (d, *J* = 8.8 Hz, 2H), 5.97 – 5.88 (m, 1H), 5.29 – 5.23 (m, 2H), 3.80 (s, 1H), 3.27 (t, *J* = 6.7 Hz, 2H),

2.50 (q, *J* = 6.7 Hz, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 147.3, 135.6, 132.0, 117.4, 114.5, 108.9, 42.9, 33.5.

N-(but-3-en-1-yl)-3-iodoaniline **(1g)** Colorless oil, 128.2 mg, 47% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 7.02 (d, J = 7.7 Hz, 1H), 6.99 – 6.92 (m, 1H), 6.88 (t, J = 8.0 Hz, 1H), 6.56 (dd, J = 8.2, 2.2 Hz, 1H), 5.82 (ddt, J = 17.0, 10.1, 6.8 Hz, 1H), 5.29 – 4.97 (m, 2H), 3.69 (s, 1H), 3.16 (dd, J = 11.9, 6.4 Hz, 2H), 2.39 (dt, J = 7.9, 6.1 Hz, 2H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 149.4, 135.4, 130.6, 126.1, 121.3, 117.4, 112.2, 95.3, 42.5, 33.4.

3-bromo-N-(but-3-en-1-yl)aniline **(1h)** Colorless oil,

115.3 mg, 51% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 7.02 (t, *J* = 8.0 Hz, 1H), 6.81 (d, *J* = 7.1 Hz, 1H), 6.75 (d, *J* = 1.7 Hz, 1H), 6.52 (dd, *J* = 8.2, 2.1 Hz, 1H), 5.75-5.63 (m, 1H), 5.15 (t, *J* = 13.2 Hz, 2H), 3.74 (s, 1H), 3.17 (dd, *J* = 12.2, 6.4 Hz, 2H), 2.39 (q, *J* = 6.7 Hz, 2H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 149.5, 135.4, 130.5, 123.3, 120.0, 117.4, 115.3, 111.6, 42.6, 33.4.

N-(but-3-en-1-yl)-2-iodo-4-methylaniline **(1i)** Colorless oil, 206.7 mg, 72 % yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.50 (d, *J* = 1.7 Hz, 1H), 7.02 (dd, *J* = 8.2, 1.7 Hz, 1H), 6.48 (d, *J* = 8.2 Hz, 1H), 5.85 (ddt, *J* = 17.1, 10.2, 6.9 Hz, 1H), 5.23 – 5.10 (m, 2H), 4.05 (s, 1H), 3.20 (t, *J* = 6.7 Hz, 2H), 2.43 (q, *J* = 6.8 Hz, 2H), 2.21 (s, 3H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 144.9, 139.1, 135.3, 129.8, 127.8, 117.3, 110.5, 85.3, 43.3, 33.3, 19.6.

N-(but-3-en-1-yl)-4-(trifluoromethyl)aniline **(1j)** Colorless oil, 124.7 mg, 58% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.45 - 7.30 (m, 2H), 6.68 (d, J = 8.3 Hz, 2H), 6.59 (d, J = 8.5 Hz, 2H), 5.81 (dd, J = 17.1, 10.2 Hz, 2H), 5.14 (dd, J = 12.7, 11.0 Hz, 3H), 3.97 (s, 3H), 3.21 (t, J = 6.7 Hz, 3H), 2.39 (d, J = 6.7 Hz, 3H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 150.4, 135.2, 126.6, 126.5, 117.4, 112.0, 42.4, 33.3. **^{19}F NMR (376 MHz, $CDCl_3$)** δ -61.02.

N-(but-3-en-1-yl)-4-methoxyaniline **(1k)** Colorless oil, 108.1 mg, 61% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 6.80 (d, *J* = 8.9 Hz, 2H), 6.60 (d, *J* = 8.9 Hz, 2H), 5.87 – 5.80 (m, 1H), 5.19 – 5.07 (m, 2H), 3.75 (s, 3H), 3.32 (s, 1H), 3.15 (t, *J* = 6.7 Hz, 2H), 2.38 (q, *J* = 6.7 Hz, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 152.2, 142.6, 136.0, 117.1, 115.0, 114.3, 55.8, 43.9, 33.8.

4-(but-3-en-1-ylamino)benzonitrile **(1l)** Colorless oil, 86 mg, 50% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.41 (d, *J* = 8.8 Hz, 2H), 6.55 (d, *J* = 8.8 Hz, 2H), 5.80 (ddt, *J* = 17.1, 10.2, 6.8 Hz, 1H), 5.20 – 5.08 (m, 2H), 4.24 (s, 1H), 3.22 (t, *J* = 6.7 Hz, 2H), 2.39 (q, *J* = 6.7, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 151.2, 135.0, 133.7, 120.5, 117.7, 112.2, 98.6, 42.0, 33.2.

N-(but-3-en-1-yl)-4-(trifluoromethoxy)aniline **(1m)**

Colorless oil, 111 mg, 48% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.03 (d, *J* = 8.9 Hz, 2H), 6.60 (d, *J* = 9.0 Hz, 2H), 5.87 – 5.78 (m, 1H), 5.25 – 5.14 (m, 2H), 3.78 (s, 1H), 3.21 (t, *J* = 6.7 Hz, 2H), 2.43 (q, *J* = 6.7 Hz, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 146.9, 140.3, 135.4, 124.5, 122.3, 121.9, 120.7 (q, *J* = 257 Hz), 119.4, 117.2, 116.8, 112.9, 42.8, 33.4. **^{19}F NMR (376 MHz, $CDCl_3$)** δ -58.31.

N-(but-3-en-1-yl)-4-nitroaniline **(1n)** Yellow solid, 38.4 mg, 20% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 8.09 (d, *J* = 9.2 Hz, 2H), 6.53 (d, *J* = 9.2 Hz, 2H), 5.87– 5.77 (m, 1H), 5.26 – 5.11 (m, 2H), 4.50 (s, 1H), 3.29 (dd, *J* = 12.1, 6.6 Hz, 2H), 2.43 (q, *J* = 6.7 Hz, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 153.3, 138.2, 134.9, 126.6, 118.2, 111.2, 42.3, 33.3.

N-(but-3-en-1-yl)-2-(trifluoromethyl)aniline **(1o)** Colorless oil, 131.3 mg, 61% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.79 - 7.19 (m, 2H), 6.95 - 6.62 (m, 2H), 5.92-5.80 (m, 1H), 5.69 - 5.02 (m, 2H), 4.55 (s, 1H), 3.39 (t, *J* = 6.4 Hz, 2H), 2.59 (ddd, *J* = 6.7, 6.2, 1.2 Hz, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 145.8, 135.2, 133.2, 126.8, 126.7, 124.0, 117.7, 115.9, 111.9, 42.5, 33.4. **^{19}F NMR (376 MHz, $CDCl_3$)** δ -62.44.

N-(but-3-en-1-yl)-3,5-bis(trifluoromethyl)aniline **(1p)** Colorless oil, 113.3 mg, 40% yield**. ^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.04 (s, 1H), 6.83 (s, 2H), 5.72 (td, *J* = 16.8, 6.6 Hz, 1H), 5.16 - 5.03 (m, 2H), 4.01 (s, 1H), 3.14 (dd, *J* = 12.1, 6.3 Hz, 2H), 2.33 (q, *J* = 6.7 Hz, 2H), 1.45 (s, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 148.3, 134.5, 124.5, 121.8, 117.5, 111.4, 109.7, 41.9, 32.8. **^{19}F NMR (376 MHz, $CDCl_3$)** δ -63.54.

N-(but-3-en-1-yl)-3-(trifluoromethyl)aniline **(1q)** Colorless oil, 116.2 mg, 54% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.30 (dd, *J* = 9.2, 6.6 Hz, 1H), 6.97 (d, *J* = 7.6 Hz, 1H), 6.84 (s, 1H), 6.78 (d, *J* = 8.2 Hz, 1H), 5.87 (ddt, *J* = 17.0, 10.1, 6.8 Hz, 1H), 5.44 – 4.88 (m, 2H), 3.91 (s, 1H), 3.26 (s, 2H), 2.57 – 2.29 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 148.4, 135.4, 131.7, 131.4, 129.6, 125.7, 123.0, 117.5, 115.8, 113.7, 113.7, 108.9, 108.9, 42.5, 33.4. **^{19}F NMR (376 MHz, $CDCl_3$)** δ -62.90.

N-(but-3-en-1-yl)-[1,1'-biphenyl]-4-amine **(1r)** Colorless oil, 160.8 mg, 72% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.42 (d, *J* = 7.8 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.27 (t, *J* = 7.4 Hz, 2H), 7.20 – 7.10 (m, 1H), 6.56 (d, *J* = 8.4 Hz, 2H), 5.86 – 5.61 (m, 1H), 5.03 (t, *J* = 14.5 Hz, 2H), 3.63 (s, 1H), 3.11 (t, *J* = 6.7 Hz, 2H), 2.29 (q, *J* = 6.6 Hz, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 147.5, 141.1, 135.6, 130.1, 128.5, 127.8, 126.1, 125.9, 117.0, 113.0, 42.7, 33.5.

N-(but-3-en-1-yl)-[1,1'-biphenyl]-2-amine **(1s)** Colorless oil , 133.9 mg, 60% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 7.48 – 7.31 (m, 5H), 7.28 – 7.21 (m, 1H), 7.10 (d, *J* = 7.4 Hz, 1H), 6.77 (t, *J* = 7.4 Hz, 1H), 6.73 – 6.68 (m, 1H), 5.94 – 5.50 (m, 1H), 5.00 (dd, *J* = 8.6, 6.5 Hz, 2H), 3.99 (s, 1H), 3.18 (dd, *J* = 11.8, 6.4 Hz, 2H), 2.32 (q, *J* = 6.7 Hz, 2H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 145.0, 139.4, 135.6, 130.1, 129.4, 128.8, 128.7, 127.7, 127.1, 117.0, 116.8, 110.4, 42.8, 33.5.

1-(4-(but-3-en-1-ylamino)phenyl)ethanone **(1t)** Colourless oil, 125.1 mg, 66% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.78 (d, *J* = 8.9 Hz, 2H), 6.52 (d, *J* = 8.8 Hz, 2H), 5.78 (ddt, *J* = 17.1, 10.2, 6.8 Hz, 1H), 5.20 – 5.02 (m, 2H), 4.19 (s, 1H), 3.22 (t, *J* = 6.7 Hz, 2H), 2.46 (s, 3H), 2.37 (dtd, *J* = 6.8, 5.5, 1.3 Hz, 2H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 196.1, 151.8, 134.9, 130.6, 126.5, 117.4, 111.2, 41.9, 33.1, 25.8.

(3-(but-3-en-1-ylamino)phenyl)(phenyl)methanone **(1u)** Light yellow solid, 158.3 mg, 63% yield**. ^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.81 (d, *J* = 7.7 Hz, 2H), 7.57 (t, *J* = 7.4 Hz,

1H), 7.47 (t, *J* = 7.5 Hz, 2H), 7.29 - 7.24 (m, 1H), 7.06 (d, *J* = 6.5 Hz, 2H), 6.82 (d, *J* = 8.3 Hz, 1H), 5.77-5.66 (m, 1H), 5.14 (t, *J* = 13.2 Hz, 2H), 3.81 (s, 1H), 3.22 (t, *J* = 6.7 Hz, 2H), 2.46 - 2.31 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 197.2, 148.2, 138.6, 137.9, 135.5, 132.2, 130.0, 128.9, 128.1, 119.6, 117.4, 116.9, 113.5, 42.7, 33.5.

N-(but-3-en-1-yl)benzo[d][1,3]dioxol-5-amine **(1v)** Colorless oil, 86.0 mg, 45% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 6.67 (d, *J* = 8.3 Hz, 1H), 6.26 (s, 1H), 6.07 (d, *J* = 8.3 Hz, 1H), 5.97 - 5.74 (m, 3H), 5.10-5.01 (m, 2H), 3.45 (s, 1H), 3.13 (td, *J* = 6.7, 1.4 Hz, 2H), 2.44 - 2.31 (m, 2H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 148.3, 144.1, 139.6, 135.7, 117.1, 108.6, 104.5, 100.5, 96.1, 43.8, 33.6.

methyl 3-(but-3-en-1-ylamino)thiophene-2-carboxylate **(1w)** colorless liquid, 109.8 mg, 52% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 7.33 (d, *J* = 5.5 Hz, 1H), 6.76 (s, 1H), 6.63 (d, *J* = 5.5 Hz, 1H), 5.86 –5.79 (m, 1H), 5.18 – 5.11 (m, 2H), 3.81 (s, 3H), 3.34 (d, *J* = 2.7 Hz, 2H), 2.50 – 2.28 (m, 2H).. **^{13}C NMR (100 MHz, $CDCl_3$)** δ 165.4, 156.1, 135.1, 132.2, 117.4, 116.2, 98.5, 51.1, 44.4, 34.3.

N-(but-3-en-1-yl)-6-chloropyridin-3-amine **(1x)** Colorless oil, 98.6 mg, 44% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 7.77 (s, 1H), 7.09 (d, *J* = 8.6 Hz, 1H), 6.87 (d, *J* = 8.6, 1H), 5.76-5.64 (m, 1H), 5.16 (dd, *J* = 13.3, 6.3 Hz, 2H), 3.74 (s, 1H), 3.18 (dd, *J* = 12.5, 6.4 Hz, 2H), 2.40 (q, *J* = 6.7 Hz, 2H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 143.2, 139.0, 135.0, 134.5, 124.0, 122.2, 117.7, 42.5, 33.3.

N-(but-3-en-1-yl)-4-chloropyridin-2-amine **(1y)** Colorless oil, 122.2 mg, 67% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 8.03 (s, 1H), 7.36 (d, *J* = 8.8, 1H), 6.33 (d, *J* = 8.9 Hz, 1H), 5.93 – 5.69 (m, 1H), 5.34 – 4.99 (m, 2H), 4.53 (s, 1H), 3.41 – 3.27 (m, 2H), 2.38 (dt, *J* = 6.6, 5.5 Hz, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 143.4, 138.8, 135.1, 134.5, 124.1, 122.3, 117.7, 42.6, 33.4.

N-(but-3-en-1-yl)-5-chloropyrazin-2-amine **(1z)** Colorless oil, 117.4 mg, 64% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 8.00 (d, *J* = 1.2 Hz, 1H), 7.64 (d, *J* = 1.2 Hz, 1H), 5.76-5.65 (m, 1H), 5.32 – 4.98 (m, 2H), 4.68 (s, 1H), 3.40 (dd, *J* = 12.4, 6.6 Hz, 2H), 2.40 (q, *J* = 6.7 Hz, 2H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 153.3, 141.2, 136.0, 135.0, 129.9, 117.7, 40.7, 33.4.

N-(but-3-en-1-yl)-4-methylbenzenesulfonamide **(1aa)** white solid, 168.8 mg, 75% yield**. ^{1}H NMR (500 MHz, $CDCl_3$)** δ 7.74 (d, *J* = 8.2 Hz, 2H), 7.30 (d, *J* = 8.1 Hz, 2H), 5.62 (ddt, *J* = 17.1, 10.3, 6.8 Hz, 1H), 5.04 (t, *J* = 12.6 Hz, 2H), 4.61 (bs, 1H), 3.00 (q, *J* = 6.5 Hz, 2H), 2.42 (s, 3H), 2.19 (q, *J* = 6.8 Hz, 2H).**^{13}C NMR (126 MHz, $CDCl_3$)** δ 143.2, 136.7, 134.0, 129.5, 126.9, 117.9, 77.1, 76.8, 76.5, 41.9, 33.4, 21.3.

N-(but-3-en-1-yl)-4-methoxybenzenesulfonamide **(1ab)** white solid, 173.6 mg, 72% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.74 (d, *J* = 8.9 Hz, 2H), 6.91 (d, *J* = 8.9 Hz, 2H), 5.72 - 5.39 (m, 1H), 5.13 – 4.78 (m, 2H), 4.65 (d, *J* = 6.0 Hz, 1H), 3.80 (d, *J* = 0.6 Hz, 3H), 3.07 – 2.71 (m, 2H), 2.13 (q, *J* = 6.8 Hz, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 162.8, 134.1, 131.4, 129.1, 117.9, 114.2, 55.6, 42.0, 33.5.

4-bromo-N-(but-3-en-1-yl)benzenesulfonamide **(1ac)** white solid , 220.4 mg, 76% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 7.77 - 7.69 (m, 2H), 7.68 - 7.62 (m, 2H), 5.58-5.46 (m, 1H), 5.16 - 4.95 (m, 2H), 4.90 (s, 1H), 3.03 (dd, *J* = 12.9, 6.7 Hz, 2H), 2.22 (qt, *J* = 6.8, 1.3 Hz, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 139.0, 133.9, 132.3, 128.6, 127.5, 118.2, 42.1, 33.6.

N-(but-3-en-1-yl)-2-ethylhexan-1-amine **(1ad)** light yellow oil, 69.6 mg, 38% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 5.78 (m, *J* = 13.7, 10.2, 5.1 Hz, 1H), 5.18 - 4.93 (m, 2H), 2.66 (t, *J* = 6.9 Hz, 2H), 2.49 (d, *J* = 6.2 Hz, 2H), 2.32 - 2.13 (m, 2H), 1.52 – 1.36 (m, 1H), 1.35 - 1.20 (m, 7H), 0.88 (m, 6H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 136.6, 116.1, 53.1, 49.2, 39.4, 34.3, 31.4, 29.0, 24.5, 23.1, 14.1, 10.8.

N-phenethylbut-3-en-1-amine **(1ae)** light yellow oil, 105.2 mg, 60% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.56 – 7.33 (m, 5H), 5.99 – 5.90 (m, 1H), 5.30 – 5.15 (m, 2H), 3.13 – 3.05 (m, 2H), 3.03 – 2.97 (m, 2H), 2.90 (t, *J* = 6.9 Hz, 2H), 2.44 (q, *J* = 6.9 Hz, 2H), 1.31 (s, 1H).. **^{13}C NMR (100 MHz, $CDCl_3$)** δ 140.2, 136.5, 128.8, 128.5, 126.2, 116.4, 51.2, 48.9, 36.5, 34.4.

N-(4-methoxyphenethyl)but-3-en-1-amine **(1af)** light yellow oil, 127.2 mg, 62% yield**. ^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.21 (d, *J* = 8.5 Hz, 2H), 6.92 (d, *J* = 8.6 Hz, 2H), 5.79 – 5.67 (m, 1H), 5.25 – 4.97 (m, 2H), 3.87 (s, 2H), 2.98 – 2.90 (m, 2H), 2.86 – 2.74 (m, 2H), 2.32 (q, *J* = 6.9 Hz, 2H), 1.83 (s, 1H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 158.1, 136.4, 132.1, 129.7, 116.4, 113.9, 55.3, 51.3, 48.8, 35.5, 34.3.

N-benzylbut-3-en-1-amine **(1ag)** light yellow oil, 107.9 mg, 67% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ = 7.39 – 7.19 (m, 5H), 5.84 – 5.74 (m, 1H), 5.16 – 4.98 (m, 2H), 3.79 (s, 2H), 2.70 (t, *J*=6.8, 2H), 2.28 (dt, *J*=6.9, 6.2, 2H), 1.29 (s, 1H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 140.4, 136.5, 128.4, 128.1, 126.9, 116.3, 53.9, 48.3, 34.3.

(R)-N-(1-phenylethyl)but-3-en-1-amine **(1ah)** light yellow oil, 129.6 mg, 74% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 8.15 – 6.33 (m, 5H), 5.69 – 5.58 (m, 1H), 5.31 – 4.69 (m, 2H), 3.76 (q, *J* = 6.6 Hz, 1H), 2.72 – 2.36 (m, 2H), 2.29 – 2.07 (m, 2H), 1.34 (d, *J* = 6.6 Hz, 3H), 1.27 (s, 1H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 145.7, 136.5, 128.4, 126.8, 126.5, 116.2, 58.2, 46.5, 34.3, 24.3.

N-(3-methylbut-3-en-1-yl)aniline **(3a)** light yellow oil, 106.4 mg, 66% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.19 (t, *J* = 7.6 Hz, 2H), 6.71 (t, *J* = 7.2 Hz, 1H), 6.62 (d, *J* = 8.2 Hz, 2H), 4.87 (s, 1H), 4.81 (s, 1H), 3.65 (s, 1H), 3.23 (t, *J* = 6.7 Hz, 2H), 2.36 (t, *J* = 6.6 Hz, 2H), 1.77 (s, 3H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 148.3, 142.9, 129.2, 117.3, 112.8, 112.3, 41.3, 37.4, 21.9.

N-(3-bromobut-3-en-1-yl)aniline **(3b)** light yellow oil, 144.6 mg, 64% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 7.26 - 7.17 (m, 2H), 6.75 (td, *J* = 7.4, 1.0 Hz, 1H), 6.71 - 6.58 (m, 2H), 5.75 - 5.63 (m, 1H), 5.55 (d, *J* = 1.6 Hz, 1H), 3.77 (s, 1H), 3.41 (t, *J* = 6.5 Hz, 2H), 2.74 (t, *J* = 6.5 Hz, 2H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 147.6, 131.3, 129.3, 118.9, 117.7, 113.0, 41.6, 40.9.

N-(2-(6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethyl)aniline **(3c)** colorless liquid, 139.9 mg, 58% yield. **^{1}H NMR (400**

MHz, $CDCl_3$) δ 7.25 – 7.11 (m, 2H), 6.72 (tt, *J* = 7.4, 1.0 Hz, 1H), 6.65 – 6.55 (m, 2H), 5.37 (dt, *J* = 4.2, 1.3 Hz, 1H), 3.66 (s, 1H), 3.27 – 2.93 (m, 2H), 2.41 (dt, *J* = 8.6, 5.6 Hz, 1H), 2.36 – 2.24 (m, 4H), 2.17 – 1.99 (m, 2H), 1.41 – 1.22 (m, 5H), 0.93 – 0.81 (m, 4H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 148.4, 145.6, 129.2, 118.7, 117.2, 112.9, 45.4, 41.2, 40.8, 38.0, 36.5, 31.8, 31.4, 26.3, 22.7, 21.2, 14.2.

(E)-N-(pent-3-en-1-yl)aniline **(3d)** light yellow liquid, 111.2 mg, 69% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.18 (t, *J* = 7.9 Hz, 2H), 6.70 (t, *J* = 7.3 Hz, 1H), 6.61 (d, *J* = 8.1 Hz, 2H), 5.54-5.44 (m, 1H), 5.50 - 5.37 (m, 1H), 3.65 (s, 1H), 3.13 (t, *J* = 6.7 Hz, 2H), 2.31 (q, *J* = 6.7 Hz, 2H), 1.70 (d, *J* = 6.0 Hz, 3H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 148.4, 129.2, 128.2, 127.7, 117.2, 112.8, 43.3, 32.4, 18.0.

N-(4-methylpent-3-en-1-yl)aniline **(3e)** light yellow oil, 114 mg, 65% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.30 (t, *J* = 7.7 Hz, 2H), 6.82 (t, *J* = 7.3 Hz, 1H), 6.74 (d, *J* = 8.0 Hz, 2H), 5.28 (t, *J* = 7.2 Hz, 1H), 3.76 (s, 1H), 3.24 (t, *J* = 6.9 Hz, 2H), 2.44 (d, *J* = 7.0 Hz, 2H), 1.86 (s, 3H), 1.77 (s, 3H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 148.5, 134.4, 129.3, 121.4, 117.3, 113.0, 43.9, 28.2, 25.9, 18.0.

2.3 Procedure for the synthesis of 4-chloropiperidines, 2 and 4.

A glass vial equipped with a screw cap and a stirring bar was charged with alkene **1** (0.5 mmol). Then ethyl acetate was added (2.5 mL) followed by DMSO (2.4 mmol) and HCl/DMPU (102 µL, 2.4 mmol). We stirred the reaction mixture at 65 °C and monitored the progress of the reaction by GC-MS or TLC. Upon completion, the reaction mixture was quenched with water and extracted with DCM. The combined organic layers were then dried over anhydrous Na_2SO_4, filtered, and the solvent evaporated. We purified the crude product by silica gel column chromatography (hexanes/ethyl acetate typically 97/3).

4-chloro-1-phenylpiperidine **(2a)** Colorless oil, 92.6 mg, 95% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.23 (t, *J* = 8.0 Hz, 2H), 6.92 (d, *J* = 8.0 Hz, 2H), 6.82 (t, *J* = 7.3 Hz, 1H), 4.25 – 4.14 (m, 1H), 3.54 – 3.45 (m, 2H), 3.07 – 2.97 (m, 2H), 2.25 – 2.15 (m, 2H), 2.03 – 1.92 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 151.1, 129.2, 119.8, 116.6, 57.2, 47.5, 35.1. **HRMS (EI+)** calcd. for [$C_{11}H_{14}NCl$] (MH^+) 196.1044; found 196.1041.

4-chloro-1-(p-tolyl)piperidine **(2b)** Colorless oil, 89.1 mg, 85% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ = 7.05 (d, *J*=7.7, 2H), 6.83 (d, *J*=7.5, 2H), 4.16 (*bs*, 1H), 3.42 – 3.44 (m, 2H), 2.99 – 2.95 (m, 2H), 2.29 – 2.12 (m, 5H), 2.00 – 1.98 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 149.0, 129.6, 129.3, 116.9, 57.1, 48.1, 35.2, 20.4. **HRMS (EI+)** calcd. for [$C_{12}H_{17}NCl$] (MH^+) 210.1044; found 210.1042.

4-chloro-1-(m-tolyl)piperidine **(2c)** Colorless oil, 97.5 mg, 93% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.16 (t, *J* = 7.7 Hz, 1H), 6.76 (d, *J* = 8.4 Hz, 2H), 6.70 (d, *J* = 7.4 Hz, 1H), 4.23 – 4.17 (m, 1H), 3.55 – 3.47 (m, 2H), 3.09 – 2.99 (m, 2H), 2.32 (s, 3H), 2.26 – 2.17 (m, 2H), 2.06 – 1.95 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 151.1, 138.9, 129.0, 120.8, 117.5, 113.7, 57.2, 47.7, 35.1, 21.8. **HRMS (EI+)** calcd. for [$C_{12}H_{17}NCl$] (MH^+) 210.1044; found 210.1042.

4-chloro-1-(4-fluorophenyl)piperidine **(2d)** Colorless oil, 89.5 mg, 84% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.01 – 6.84 (m, 4H), 4.19 (tt, *J* = 8.0, 3.9 Hz, 1H), 3.45 – 3.31 (m, 2H), 3.02 – 2.93 (m, 2H), 2.22 (dtd, *J* = 10.4, 7.0, 3.6 Hz, 2H), 2.09 – 1.95 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 158.3, 155.9, 147.7, 118.4, 115.5, 115.3, 56.7, 48.3, 35.0. **^{19}F NMR (376 MHz, $CDCl_3$)** δ -124.31 (s, 1H). **HRMS (EI+)** calcd. for [$C_{11}H_{13}ClFN$] (M^+) 213.0719; found 213.0714.

4-chloro-1-(4-chlorophenyl)piperidine **(2e)** Colorless oil, 104.7 mg, 91 % yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.20 (d, *J* = 9.0 Hz, 2H), 6.85 (d, *J* = 8.7 Hz, 2H), 4.21 (tt, *J* = 7.6, 3.7 Hz, 1H), 3.52 – 3.35 (m, 2H), 3.13 – 2.97 (m, 2H), 2.27 – 2.11 (m, 2H), 2.06 – 1.92 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 149.6, 129.0, 124.6, 117.7, 56.8, 47.4, 34.8. **HRMS (EI+)** calcd. for [$C_{11}H_{14}NCl_2$] (MH^+) 230.0498; found 230.0496.

1-(4-bromophenyl)-4-chloropiperidine **(2f)** Colorless oil, 109.9 mg, 80% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.33 (d, *J* = 9.0 Hz, 2H), 6.80 (d, *J* = 9.0 Hz, 2H), 4.21 (tt, *J* = 7.8, 3.9 Hz, 1H), 3.51 – 3.39 (m, 2H), 3.12 – 2.94 (m, 2H), 2.20 (dtd, *J* = 10.5, 7.0, 3.6 Hz, 2H), 2.06 – 1.94 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 150.0, 131.9, 129.1, 118.1, 56.8, 47.2, 34.7. **HRMS (EI+)** calcd. for [$C_{11}H_{14}NBrCl$] (MH^+) 273.9993; found 273.9989.

4-chloro-1-(3-iodophenyl)piperidine **(2g)** Colorless oil, 112.3 mg, 70% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.25 – 7.23 (m, 1H), 7.18 – 7.13 (m, 1H), 6.98 – 6.93 (m, 1H), 6.87 (ddd, *J* = 8.4, 2.4, 0.8 Hz, 1H), 4.21 (tt, *J* = 7.8, 3.8 Hz, 1H), 3.53 – 3.44 (m, 2H), 3.12 – 3.01 (m, 2H), 2.18 (ddd, *J* = 13.1, 6.8, 3.3 Hz, 2H), 2.03 – 1.92 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$** δ 152.1, 130.5, 128.4, 125.2, 115.6, 95.2, 56.8, 46.9, 34.7. **HRMS (EI+)** calcd. for [$C_{11}H_{13}ClIN$] (M^+) 320.9781; found 320.9775.

1-(3-bromophenyl)-4-chloropiperidine **(2h)** Colorless oil, 137 mg, 86% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.11 (t, *J*=8.1, 1H), 7.05 (t, *J*=2.1, 1H), 6.96 (ddd, *J*=7.8, 1.8, 0.8, 1H), 6.87 – 6.81 (m, 1H), 4.22 (tt, *J*=7.8, 3.8, 1H), 3.57 – 3.45 (m, 2H), 3.15 – 3.04 (m, 2H), 2.25 – 2.15 (m, 2H), 2.05 – 1.93 (m,2H). **^{13}C NMR (100 MHz $CDCl_3$)** δ 152.2, 130.4, 123.2, 122.2, 119.1, 114.8, 56.8, 46.8, 34.6. **HRMS (EI+)** calcd. for [$C_8H_{14}NBrClF_2$] (MH^+) 275.9970; found 275.9969.

4-chloro-1-(2-iodo-4-methylphenyl)piperidine **(2i)** Colorless oil, 106.5 mg, 81% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.48 (d, *J* = 8.8 Hz, 2H), 6.94 (d, *J* = 8.7 Hz, 2H), 4.28 – 4.28 (m, 1H), 3.64 – 3.53 (m, 2H), 3.25 – 3.15 (m, 2H), 2.23 – 2.17 (m, 2H), 2.04 – 1.91 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ = 152.7, 129.0, 126.4, 125.9, 125.6, 123.2, 120.5, 114.8, 58.6, 45.9, 34.3. **^{19}F NMR (376 MHz, $CDCl_3$)** δ -61.35. **HRMS (EI+)** calcd. for [$C_{12}H_{13}ClF_3N$] (M^+) 263.0691; found 263.0686.

4-chloro-1-(4-(trifluoromethyl)phenyl)piperidine **(2j)** Colorless oil, 106.5 mg, 81% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.48 (d, *J* = 8.8 Hz, 2H), 6.94 (d, *J* = 8.7 Hz, 2H), 4.28 – 4.28 (m, 1H), 3.64 – 3.53 (m, 2H), 3.25 – 3.15 (m, 2H), 2.23 – 2.17 (m, 2H), 2.04 – 1.91 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ = 152.7, 129.0, 126.4, 125.9, 125.6, 123.2, 120.5, 114.8, 58.6, 45.9, 34.3. **^{19}F NMR (376 MHz, $CDCl_3$)** δ -61.35. **HRMS (EI+)** calcd. for [$C_{12}H_{13}ClF_3N$] (M^+) 263.0691; found 263.0686.

4-chloro-1-(4-methoxyphenyl)piperidine **(2k)** Colorless oil, 101.5 mg, 90% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ = 6.93 (d, *J*=9.0, 2H), 6.85 (d, *J*=8.9, 2H), 4.24 – 4.12 (m, 1H), 3.79 (s, 3H), 3.46 – 3.34 (m, 2H), 3.00 – 2.90 (m, 2H), 2.22 (s, 2H), 2.12 – 2.00 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 153.9, 145.6, 118.8, 114.4, 57.1, 55.5, 49.1, 35.4. **HRMS (EI+)** calcd. for [$C_{12}H_{17}ONCl$] (MH^+) 226.0993; found 226.0990.

4-(4-chloropiperidin-1-yl)benzonitrile **(2l)** Colorless oil, 79.4 mg, 72% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.49 (d, *J* = 9.0 Hz, 2H), 6.87 (d, *J* = 9.0 Hz, 2H), 4.31 – 4.26 (m, 1H), 3.69 – 3.57 (m, 2H), 3.32 – 3.26 (m, 2H), 2.21 – 2.14 (m, 2H), 2.00 – 1.92 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 152.7, 133.4, 119.8, 114.3, 100.0, 56.3, 44.9, 34.1. **HRMS (EI+)** calcd. for [$C_{12}H_{14}N_2Cl$] (MH^+) 221.0840; found 221.0837.

4-chloro-1-(4-(trifluoromethoxy)phenyl)piperidine **(2m)** Colorless oil, 126 mg, 90 % yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ = 7.11 (d, *J*=8.7, 2H), 6.90 (d, *J*=8.9, 2H), 4.22 (dt, *J*=11.7, 3.8, 1H), 3.53 – 3.44 (m, 2H), 3.13 – 3.03 (m, 2H), 2.21 (dd, *J*=14.6, 11.6, 2H), 2.06 – 1.96 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 149.7, 141.9, 124.2, 121.8, 121.6, 119.2, 117.1, 116.8, 114.4, 56.6, 47.3, 34.7. **^{19}F NMR (376 MHz, $CDCl_3$)** δ = -58.32. **HRMS (EI+)** calcd. for [$C_{12}H_{14}ONClF_3$] (MH^+) 280.0711; found 280.0708.

4-chloro-1-(4-nitrophenyl)piperidine **(2n)** Yellow solid, 72.0 mg, 60% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 8.10 (d, *J* = 9.4 Hz, 2H), 6.82 (d, *J* = 9.4 Hz, 2H), 4.32 (dq, *J* = 10.8, 3.7 Hz, 1H), 3.78 – 3.65 (m, 2H), 3.40 (ddd, *J* = 11.5, 7.3, 3.6 Hz, 2H), 2.26 – 2.11 (m, 2H), 2.01 – 1.93 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 154.4, 138.4, 126.1, 112.9, 56.3, 44.9, 34.3. **HRMS (EI+)** calcd. for [$C_{11}H_{13}ClN_2O_2$] (M^+) 240.0669; found 240.0664.

4-chloro-1-(2-(trifluoromethyl)phenyl)piperidine **(2o)** Colorless oil, 105.4 mg, 80% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.62 (d, *J* = 7.9 Hz, 1H), 7.51 (t, *J* = 7.7 Hz, 1H), 7.37 (d, *J* = 8.1 Hz, 1H), 7.22 (t, *J* = 7.6 Hz, 1H), 4.23 (bs, 1H), 3.21 – 3.02 (m, 2H), 2.81 (ddd, *J* = 11.2, 7.7, 3.2 Hz, 2H), 2.21 (ddd, *J* = 13.5, 6.9, 3.4 Hz, 2H), 2.09 – 1.97 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 152.8, 132.9, 128.2, 127.3, 125.5, 125.0, 124.2, 122.8, 120.1, 57.4, 51.4, 35.9. **^{19}F NMR (376 MHz, $CDCl_3$)** δ -60.5, -62.21 (side product). **HRMS (EI+)** calcd. for [$C_{12}H_{14}NClF_3$] (MH^+) 264.0761; found 264.0758.

1-(3,5-bis(trifluoromethyl)phenyl)-4-chloropiperidine **(2p)** Colorless oil, 149.2 mg, 90% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.32 –7.21 (m, 3H), 4.28 (tt, *J*=7.4, 3.7, 1H), 3.64 – 3.55 (m, 2H), 3.29 – 3.19 (m, 2H), 2.22 (ddt, *J*=14.3, 7.4, 3.6, 2H), 2.06 – 1.96 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 151.3, 132.8, 132.5, 132.2, 131.8, 127.5, 124.8, 122.1, 119.4, 115.0, 112.0, 56.0, 46.0, 34.3. **^{19}F NMR (376 MHz, $CDCl_3$)** δ = -63.10. **HRMS (EI+)** calcd. for [$C_{13}H_{13}NClF_6$] (MH^+) 332.0635; found 332.0632.

4-chloro-1-(3-(trifluoromethyl)phenyl)piperidine **(2q)** Colorless oil, 95 mg, 72% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.35 (t, *J* = 8.0 Hz, 1H), 7.12 (s, 1H), 7.08 (d, *J* = 8.2 Hz, 2H), 4.24 (tt, *J* = 7.8, 3.8 Hz, 1H), 3.60 – 3.48 (m, 2H), 3.20 – 3.08 (m, 2H), 2.29 – 2.15 (m, 2H), 2.07 – 1.94 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 151.1, 131.9, 131.6, 131.3, 131.0, 130.0, 125.6, 122.9, 119.2, 115.8, 112.6, 56.6, 46.8, 34.7**. ^{19}F NMR (376 MHz, $CDCl_3$)** δ -62.83. **HRMS (EI+)** calcd. for [$C_{12}H_{14}NClF_3$] (MH^+) 264.0761; found 264.0760.

1-([1,1'-biphenyl]-4-yl)-4-chloropiperidine **(2r)** White solid, 111.4 mg, 82% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.47 (d, *J* = 7.6 Hz, 2H), 7.43 (d, *J* = 8.6 Hz, 2H), 7.32 (t, *J* = 7.6 Hz, 2H), 7.19 (dd, *J* = 14.7, 7.2 Hz, 1H), 6.91 (d, *J* = 8.6 Hz, 2H), 4.16 – 4.10 (m, 1H), 3.51 – 3.43 (m, 2H), 3.08 – 2.97 (m, 2H), 2.19 – 2.08 (m, 2H), 1.99 – 1.87 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 150.1, 140.7, 132.2, 128.6, 127.7, 126.4, 126.4, 116.5, 57.0, 47.3, 34.8. **HRMS (EI+)** calcd. for [$C_{17}H_{19}NCl$] (MH^+) 272.1201; found 272.1200.

1-([1,1'-biphenyl]-2-yl)-4-chloropiperidine **(2s)** Colorless oil, 114.1 mg, 84% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.65 – 7.60 (m, 2H), 7.42 (dd, *J*=10.5, 4.7, 2H), 7.34 – 7.24 (m, 3H), 7.08 (ddd, *J*=11.9, 9.2, 4.6, 2H), 4.13 – 3.97 (m, 1H), 3.18 – 3.07 (m, 2H), 2.70 (ddd, *J*=11.8, 8.8, 2.9, 2H), 2.01 – 1.93 (m, 2H), 1.86 – 1.71 (m, 2H)**. ^{13}C NMR (100 MHz, $CDCl_3$)** δ 150.2, 141.0, 135.1, 131.3, 128.6, 128.1, 126.7, 122.7, 118.5, 57.3, 49.4, 35.6. **HRMS (EI+)** calcd. for [$C_{17}H_{19}NCl$] (MH^+) 272.1201; found 272.1199.

1-(4-(4-chloropiperidin-1-yl)phenyl)ethanone **(2t)** Colorless oil, 97.4 mg, 82% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.87 (d, *J*=9.0, 2H), 6.87 (d, *J*=9.0, 2H), 4.28 (tt, *J*=7.6, 3.8, 1H), 3.68 (ddd, *J*=12.8, 7.3, 3.6, 2H), 3.29 (ddd, *J*=13.2, 7.8, 3.5, 2H), 2.52 (s, 3H), 2.05-1.95 (m, 2H), 1.96 (dtd, *J*=11.3, 7.7, 3.6, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 196.4, 153.6, 130.4, 127.5, 113.6, 56.7, 45.3, 34.4, 26.1. **HRMS (EI+)** calcd. for [$C_{13}H_{17}ONCl$] (MH^+) 238.0993; found 238.0991.

(3-(4-chloropiperidin-1-yl)phenyl)(phenyl)methanone **(2u)** Colorless liquid, 111 mg, 74 % yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.80 (d, *J* = 7.5 Hz, 2H), 7.58 (t, *J* = 7.4 Hz, 1H), 7.48 (t, *J* = 7.6 Hz, 2H), 7.39 (s, 1H), 7.34 (t, *J* = 7.9 Hz, 1H), 7.18 (dd, *J* = 14.1, 7.7 Hz, 2H), 4.23 (tt, *J* = 7.8, 3.8 Hz, 1H), 3.61 – 3.51 (m, 2H), 3.19 – 3.09 (m, 2H), 2.21 (bs, 2H), 2.07 – 1.96 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 196.9, 150.8, 138.4, 137.6, 132.3, 130.0, 128.8, 128.1, 121.7, 120.4, 117.1, 56.7, 47.0, 34.7. **HRMS (EI+)** calcd. for [$C_{18}H_{19}ONCl$] (MH^+) 300.1150; found 300.1150.

1-(benzo[d][1,3]dioxol-5-yl)-4-chloropiperidine **(2v)** Yellow liquid, 81.3 mg, 68 % yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 6.71 (d, *J* = 8.4 Hz, 1H), 6.56 (d, *J* = 2.3 Hz, 1H), 6.37 (dd, *J* = 8.4, 2.4 Hz, 1H), 5.90 (s, 2H), 4.17 (td, *J* = 8.0, 4.0 Hz, 1H), 3.40 – 3.27 (m, 2H), 2.92 (ddd, *J* = 12.0, 8.4, 3.4 Hz, 2H), 2.20 (dd, *J* = 16.4, 3.5 Hz, 2H), 2.08 – 1.94 (m, 2H). **^{13}C**

NMR (100 MHz, $CDCl_3$) δ 110.0, 109.7, 108.1, 100.9, 100.5, 84.4, 57.0, 49.2, 35.3. **HRMS (EI+)** calcd. for $[C_{12}H_{14}O_2NCl]$ (MH^+) 239.0713; found 239.0707.

methyl 3-(4-chloropiperidin-1-yl)thiophene-2-carboxylate **(2w)** Pale yellow oil, 80.3 mg, 62 % yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 7.38 (d, *J* = 5.4 Hz, 1H), 6.84 (d, *J* = 5.4 Hz, 1H), 4.37 – 4.19 (m, 1H), 3.84 (s, 3H), 3.57 – 3.45 (m, 2H), 3.23 – 3.11 (m, 2H), 2.28 (ddd, *J* = 13.9, 7.4, 3.9 Hz, 2H), 2.12 – 1.98 (m, 2H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 162.1, 157.6, 156.7, 131.1, 121.0, 56.9, 51.6, 49.8, 35.2. **HRMS (EI+)** calcd. for $[C_{11}H_{14}O_2NClS]$ (M^+) 259.0434; found 259.0430.

2-chloro-5-(4-chloropiperidin-1-yl)pyridine **(2x)** Yellow liquid, 91.3 mg, 79 % yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 8.15 – 8.03 (m, 1H), 7.41 (dd, *J* = 9.0, 2.7 Hz, 1H), 6.61 (d, *J* = 9.0 Hz, 1H), 4.27 (tt, *J* = 7.8, 3.8 Hz, 1H), 3.87 (ddd, *J* = 13.0, 7.1, 3.7 Hz, 2H), 3.41 (ddd, *J* = 13.3, 8.1, 3.5 Hz, 2H), 2.20 – 2.08 (m, 2H), 1.96 – 1.82 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 157.3, 146.3, 137.2, 120.0, 107.8, 57.2, 43.2, 34.4. **HRMS (EI+)** calcd. for $[C_{10}H_{13}N_2Cl_2]$ (MH^+) 231.0450; found 231.0447.

4-chloro-2-(4-chloropiperidin-1-yl)pyridine **(2y)** Colorless oil, 87.4 mg, 76% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 8.07 (d, *J*=1.5, 1H), 7.31 (s, 1H), 7.25 – 7.19 (m, 1H), 4.29 (tt, *J*=7.5, 3.8, 1H), 3.58 – 3.47 (m, 2H), 3.23 – 3.12 (m, 2H), 2.26 (ddt, *J*=14.2, 7.3, 3.6, 2H), 2.11 – 2.00 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 146.0, 141.3, 137.9, 126.2, 124.0, 56.2, 46.5, 34.4. **HRMS (EI+)** calcd. for $[C_{10}H_{12}Cl_2N_2]$ (M^+) 230.0382; found 230.0378.

2-chloro-5-(4-chloropiperidin-1-yl)pyrazine **(2z)** Brown oil, 91.7 mg, 79% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 8.06 (s, 1H), 7.88 (s, 1H), 4.34 – 4.28 (m, 1H), 3.89 – 3.81 (m, 2H), 3.55 – 3.47 (m, 2H), 2.18 – 2.11 (m, 2H), 1.97 – 1.89 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 153.4, 141.0, 136.0, 129.2, 56.6, 42.4, 34.2. **HRMS (EI+)** calcd. for $[C_9H_{12}N_3Cl_2]$ (MH^+) 232.0403; found 232.0400.

4-chloro-1-tosylpiperidine **(2aa)** White solid. 89.1 mg, 85% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.64 (d, *J* = 8.1 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 4.16 – 4.09 (m, 1H), 3.21 – 3.07 (m, 4H), 2.44 (s, 3H), 2.16 – 2.09 (m, 2H), 1.98 – 1.89 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 143.5, 132.8, 129.6, 127.4, 55.2, 42.7, 33.8, 21.4. **HRMS (EI+)** calcd. for $[C_{12}H_{17}O_2NClS]$ (MH^+) 274.0663; found 274.0660.

4-chloro-1-((4-methoxyphenyl)sulfonyl)piperidine **(2ab)** White solid, 113 mg, 78 % yield. **^{1}H NMR (400 MHz, $(CDCl_3)$)** δ 7.60 (d, *J* = 9.0 Hz, 2H), 6.91 (d, *J* = 8.9 Hz, 2H), 4.07 – 3.97 (m, 1H), 3.78 (s, 3H), 3.11 – 3.05 (m, 2H), 3.03 – 2.95 (m, 2H), 2.10 – 1.97 (m, 2H), 1.88 – 1.80 (m, 2H). **^{13}C NMR (100 MHz, $(CDCl_3)$)** δ 162.9, 129.5, 127.6, 114.1, 55.5, 55.2, 42.7, 33.9. **HRMS (EI+)** calcd. for $[C_{12}H_{17}O_3NClS]$ (MH^+) 290.0612; found 290.0610.

1-((4-bromophenyl)sulfonyl)-4-chloropiperidine **(2ac)** White solid, 120.2mg, 71 % yield. **^{1}H NMR (400 MHz, $CDCl_3$)** 7.68 (d, *J* = 8.6, 2H), 7.62 (d, *J* = 8.6, 2H), 4.17 – 4.13 (m, 1H), 3.15 (t, *J* = 5.4 Hz, 4H), 2.17 – 2.10 (m, 2H), 1.97 – 1.91 (m, 2H).**^{13}C NMR (100 MHz, $CDCl_3$)** δ 135.4, 132.6, 129.2, 128.2, 55.2, 42.9, 34.1. **HRMS (EI+)** calcd. for $[C_{11}H_{13}O_2NBrClNaS]$ (M+Na) 359.9431; found 359.9429.

4-chloro-1-(2-ethylhexyl)piperidine **(2ad)** Colorless oil, 64.4 mg, 54% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 4.01 (bs, 1H), 2.71 (bs, 2H), 2.13 (dd, *J* = 6.6, 4.4 Hz, 5H), 1.98 – 1.81 (m, 3H), 1.44 (bs, 2H), 1.29 – 1.23 (m, 7H), 0.88 (dt, *J* = 14.9, 7.1 Hz, 7H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 62.7, 58.0, 52.2, 36.5, 35.8, 31.5, 28.9, 24.7, 23.1, 14.1, 10.8. **HRMS (EI+)** calcd. for $[C_{13}H_{26}ClN]$ (M^+) 231.1756; found 231.1751.

4-chloro-1-(4-methoxyphenethyl)piperidine **(2ae)** Colorless oil, 56.9 mg, 51% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.32 – 7.10 (m, 5H), 4.01 (s, 1H), 2.78 – 2.72 (m, 4H), 2.54 (dd, *J*=9.7, 6.5, 2H), 2.27 (bs, 2H), 2.07 (d, *J*=12.4, 2H), 1.94 – 1.80 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 140.2, 128.6, 128.3, 125.9, 60.3, 57.3, 51.2, 35.5, 33.7. **HRMS (EI+)** calcd. for $[C_{13}H_{18}ClN]$ (M^+) 223.1232; found 223.1228.

4-chloro-1-(4-methoxyphenethyl)piperidine **(2af)** Colorless oil, 73.4 mg, 58% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.11 (d, *J* = 8.4 Hz, 2H), 6.83 (d, *J* = 8.5 Hz, 2H), 4.12 – 4.00 (m, 1H), 3.79 (s, 3H), 2.88 – 2.79 (m, 2H), 2.78 – 2.67 (m, 3H), 2.61 – 2.52 (m, 2H), 2.38 – 2.25 (m, 2H), 2.18 – 2.08 (m, 2H), 2.00 – 1.86 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 158.0, 132.3, 129.6, 113.8, 60.6, 57.4, 55.3, 51.3, 35.6, 32.9. **HRMS (EI+)** calcd. for $[C_{14}H_{20}ClNO]$ (M^+) 253.1232; found 253.1228.

1-benzyl-4-chloropiperidine **(2ag)** Colorless oil, 64 mg, 61% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.43 – 7.12 (m, 5H), 4.03 (bs, 1H), 3.49 (bs, 2H), 2.80 – 2.67 (m, 2H), 2.23 (s, 2H), 2.13 – 2.02 (m, 2H), 1.96 – 1.84 (m, 2H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 138.3, 129.0, 128.2, 127.0, 62.8, 57.5, 51.3, 35.6. **HRMS (EI+)** calcd. for $[C_{12}H_{16}ClN]$ (M^+) 209.0973; found 209.0967.

4-chloro-1-(1-phenylethyl)piperidine **(2ah)** Colorless liquid, 72.7 mg, 65% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.38 – 7.21 (m, 5H), 3.98 (bs, 1H), 3.44 (q, *J*=6.7, 1H), 2.86 (bs, 1H), 2.78 – 2.66 (m, 1H), 2.29 – 2.12 (m, 2H), 2.14 – 1.99 (m, 2H), 1.97 – 1.80 (m, 2H), 1.37 (d, *J*=6.7, 3H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 143.8, 128.2, 127.5, 126.9, 64.4, 57.8, 48.6, 35.9, 19.4. **HRMS (EI+)** calcd. for $[C_{13}H_{19}NCl]$ (MH^+) 224.1201; found 224.1197.

4-chloro-4-methyl-1-phenylpiperidine **(4a)** Colorless liquid, 84.9 mg, 81% yield.**^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.32 – 7.22 (m, 2H), 6.96 (d, *J* = 8.6 Hz, 2H), 6.85 (t, *J* = 7.0 Hz, 1H), 3.51 (d, *J* = 12.8 Hz, 2H), 3.25 – 3.12 (m, 2H), 1.95 (ddd, *J* = 22.6, 18.0, 8.3 Hz, 4H), 1.68 (s, 3H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 151.1, 129.1, 119.5, 116.4, 69.5, 46.0, 40.3, 33.2. **HRMS (EI+)** calcd. for $[C_{12}H_{17}NCl]$ (MH^+) 210.1044; found 210.1040.

4-bromo-4-chloro-1-phenylpiperidine **(4b)** Colorless liquid, 114.7 mg, 84% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** δ 7.28 (d, *J* = 7.9 Hz, 2H), 6.93 (d, *J* = 7.9 Hz, 2H), 6.88 (t, *J* = 7.3 Hz, 1H), 3.45 – 3.28 (m, 4H), 2.68 (ddd, *J* = 13.7, 7.1, 3.7 Hz, 2H), 2.55 (ddd, *J* = 13.7, 7.0, 3.7 Hz, 2H). **^{13}C NMR (100 MHz**

$CDCl_3$) δ 150.2, 129.1, 120.0, 116.4, 78.9, 47.5, 46.4. **HRMS (EI+)** calcd. for [$C_{11}H_{13}BrClN$] (M^+) 272.9917; found 272.9912.

4a-chloro-6,6-dimethyl-2-phenyldecahydro-5,7-methanoisoquinoline **(4c)** Colorless oil, 76.62 mg, 53% yield. **^{1}H NMR (500 MHz, $CDCl_3$)** δ 7.23 (d, *J* = 8.1 Hz, 2H), 6.91 (d, *J* = 8.1 Hz, 2H), 6.79 (t, *J* = 7.2 Hz, 1H), 3.70 – 3.60 (m, 3H), 2.79 (td, *J* = 12.6, 3.0 Hz, 1H), 2.45 – 2.38 (m, 1H), 2.23 (td, *J* = 12.1, 6.4 Hz, 1H), 2.10 (td, *J* = 12.8, 4.5 Hz, 1H), 1.92 – 1.84 (m, 2H), 1.79 (d, *J* = 10.7 Hz, 1H), 1.61 – 1.54 (m, 1H), 1.35 (d, *J* = 11.2 Hz, 1H), 1.08 (s, 3H), 1.01 (s, 3H), 0.92 (dt, *J* = 13.0, 4.4 Hz, 1H). **^{13}C NMR (126 MHz, $CDCl_3$)** δ 151.1, 129.0, 118.9, 116.3, 77.7, 55.2, 51.8, 47.5, 47.3, 39.4, 34.8, 30.5, 30.4, 29.9, 27.7, 23.2. **HRMS (EI+)** calcd. for [$C_{18}H_{24}ClN$] (M^+) 289.1595; found 289.1590.

4-chloro-3-methyl-1-phenylpiperidine **(4d)** Colorless oil, 68.1 mg, 65% yield. **^{1}H NMR (400 MHz, $CDCl_3$)** Major (anti-) diastereomer: δ 7.31 – 7.22 (m, 2H), 6.96 – 6.90 (m, 2H), 6.86 (t, *J* = 7.3 Hz, 1H), 3.73 – 3.57 (m, 3H), 2.80 (td, *J* = 12.5, 2.7 Hz, 1H), 2.50 (dd, *J* = 12.9, 10.6 Hz, 1H), 2.31 – 2.21 (m, 1H), 2.14 – 1.95 (m, 2H), 1.14 (d, *J* = 6.6 Hz, 3H). **^{13}C NMR (100 MHz, $CDCl_3$)** δ 150.7, 129.1, 119.7, 116.5, 64.7, 56.4, 49.4, 39.5, 35.8, 16.9. **HRMS (EI+)** calcd. for [$C_{12}H_{17}NCl$] (MH^+) 210.1044; found 210.1042.

ASSOCIATED CONTENT

This material is available free of charge via the internet at http://pubs.acs.org.

Copies of ^{1}H and ^{13}C NMR spectra

AUTHOR INFORMATION

Corresponding Author

gb.hammond@louisville.edu; bo.xu@dhu.edu.cn

Notes

The authors declare no competing financial interests.

AMENTcknowledgment

We are grateful to the National Institutes of Health for financial support (R01GM121660). Bo Xu is thankful to the National Science Foundation of China for financial support (NSFC-21472018). We also thank Dr. Neal Stolowich for his help in some of the NMR experiments and Angela M. Hansen for her help with HRMS analyses performed at Indiana University Bloomington Mass Spectrometry Facility (NSF Grant CHE1726633).

REFERENCES

1. (a) François - Xavier, F.; Jacques, L. Recent Advances in the Total Synthesis of Piperidine and Pyrrolidine Natural Alkaloids with Ring - Closing Metathesis as a Key Step. *Eur. J. Org. Chem.* **2003,** *2003*, 3693-3712; (b) Carmen, E.; Mercedes, A.; Joan, B. Chiral Oxazolopiperidone Lactams: Versatile Intermediates for the Enantioselective Synthesis of Piperidine - Containing Natural Products. *Chem. Eur. J.* **2006,** *12*, 8198-8207.

2. (a) Baumann, M.; Baxendale, I. R. An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles. *Beilstein J. Org. Chem.* **2013,** *9*, 2265-2319; (b) Taylor, R. D.; MacCoss, M.; Lawson, A. D. G. Rings in Drugs. *J. Med. Chem.* **2014,** *57*, 5845-5859; (c) Vitaku, E.; Smith, D. T.; Njardarson, J. T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. *J. Med. Chem.* **2014,** *57*, 10257-10274; (d) Zhang, T. Y., Chapter One - The Evolving Landscape of Heterocycles in Drugs and Drug Candidates. In *Adv. Heterocycl. Chem.*, Scriven, E. F. V.; Ramsden, C. A., Eds. Academic Press: 2017; Vol. 121, pp 1-12; (e) Ye, Z.; Adhikari, S.; Xia, Y.; Dai, M. Expedient syntheses of N-heterocycles via intermolecular amphoteric diamination of allenes. *Nat. Commun.* **2018,** *9*, 721; (f) Pethe, K.; Bifani, P.; Jang, J.; Kang, S.; Park, S.; Ahn, S.; Jiricek, J.; Jung, J.; Jeon, H. K.; Cechetto, J.; Christophe, T.; Lee, H.; Kempf, M.; Jackson, M.; Lenaerts, A. J.; Pham, H.; Jones, V.; Seo, M. J.; Kim, Y. M.; Seo, M.; Seo, J. J.; Park, D.; Ko, Y.; Choi, I.; Kim, R.; Kim, S. Y.; Lim, S.; Yim, S.-A.; Nam, J.; Kang, H.; Kwon, H.; Oh, C.-T.; Cho, Y.; Jang, Y.; Kim, J.; Chua, A.; Tan, B. H.; Nanjundappa, M. B.; Rao, S. P. S.; Barnes, W. S.; Wintjens, R.; Walker, J. R.; Alonso, S.; Lee, S.; Kim, J.; Oh, S.; Oh, T.; Nehrbass, U.; Han, S.-J.; No, Z.; Lee, J.; Brodin, P.; Cho, S.-N.; Nam, K.; Kim, J. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. *Nat. Med.* **2013,** *19*, 1157-1160.

3. (a) Julian, L. D.; Hartwig, J. F. Intramolecular Hydroamination of Unbiased and Functionalized Primary Aminoalkenes Catalyzed by a Rhodium Aminophosphine Complex. *J. Am. Chem. Soc.* **2010,** *132*, 13813-13822; (b) Takemiya, A.; Hartwig, J. F. Rhodium-Catalyzed Intramolecular, Anti-Markovnikov Hydroamination. Synthesis of 3-Arylpiperidines. *J. Am. Chem. Soc.* **2006,** *128*, 6042-6043; (c) Fujita, K.-i.; Fujii, T.; Yamaguchi, R. Cp*Ir Complex-Catalyzed N-Heterocyclization of Primary Amines with Diols: A New Catalytic System for Environmentally Benign Synthesis of Cyclic Amines. *Org. Lett.* **2004,** *6*, 3525-3528.

4. (a) Qi, X.; Chen, C.; Hou, C.; Fu, L.; Chen, P.; Liu, G. Enantioselective Pd(II)-Catalyzed Intramolecular Oxidative 6-endo Aminoacetoxylation of Unactivated Alkenes. *J. Am. Chem. Soc.* **2018,** *140*, 7415-7419; (b) Ortiz, G. X.; Kang, B.; Wang, Q. One-Pot Synthesis of 3-Azido- and 3-Aminopiperidines by Intramolecular Cyclization of Unsaturated Amines. *J. Org. Chem.* **2014,** *79*, 571-581.

5. (a) Liu, G.-Q.; Cui, B.; Xu, R.; Li, Y.-M. Preparation of trans-2-Substituted-4-halopiperidines and cis-2-Substituted-4-halotetrahydropyrans via AlCl3-Catalyzed Prins Reaction. *J. Org. Chem.* **2016,** *81*, 5144-5161; (b) Nebe, M. M.; Opatz, T., Chapter Five - Synthesis of Piperidines and Dehydropiperidines: Construction of the Six-Membered Ring. In *Adv. Heterocycl. Chem.*, Scriven, E. F. V.; Ramsden, C. A., Eds. Academic Press: 2017; Vol. 122, pp 191-244.

6. (a) Coldham, I.; Collis, A. J.; Mould, R. J.; Rathmell, R. E. Synthesis of 4-phenylpiperidines by tandem Wittig olefination – aza-Wittig rearrangement of 2-benzoylaziridines. *J. Chem. Soc., Perkin Trans. 1* **1995**, 2739-2745; (b) Coldham, I.; Collis, A. J.; Mould, R. J.; Rathmell, R. E. Ring expansion of aziridines to piperidines using the aza-Wittig rearrangement. *Tetrahedron Lett.* **1995,** *36*, 3557-3560; (c) Ohno, H. Synthesis and applications of vinyl aziridines and ethynyl aziridines. *Chem. Rev.* **2014,** *114*, 7784-814.

7. (a) Rueping, M.; Antonchick, A. P. Organocatalytic Enantioselective Reduction of Pyridines. *Angew. Chem. Int. Ed.* **2007,** *46*, 4562-4565; (b) Mahdi, T.; del Castillo, J. N.; Stephan, D. W. Metal-Free Hydrogenation of N-Based Heterocycles. *Organometallics* **2013,** *32*, 1971-1978; (c) Liu, Y.; Du, H. Metal-Free Borane-Catalyzed Highly Stereoselective Hydrogenation of Pyridines. *J. Am. Chem. Soc.* **2013,** *135*, 12968-12971; (d) Gandhamsetty, N.; Park, S.; Chang, S. Selective Silylative Reduction of Pyridines Leading to Structurally Diverse Azacyclic

Compounds with the Formation of sp3 C – Si Bonds. *J. Am. Chem. Soc.* **2015,** *137*, 15176-15184; (e) Zhou, Q.; Zhang, L.; Meng, W.; Feng, X.; Yang, J.; Du, H. Borane-Catalyzed Transfer Hydrogenations of Pyridines with Ammonia Borane. *Org. Lett.* **2016,** *18*, 5189-5191; (f) Liu, G.-Q.; Opatz, T., Chapter Two - Recent Advances in the Synthesis of Piperidines: Functionalization of Preexisting Ring Systems. In *Adv. Heterocycl. Chem.*, Scriven, E. F. V.; Ramsden, C. A., Eds. Academic Press: 2018; Vol. 125, pp 107-234.

8. (a) Ju, Y.; Varma, R. S. Aqueous N-Heterocyclization of Primary Amines and Hydrazines with Dihalides: Microwave-Assisted Syntheses of N-Azacycloalkanes, Isoindole, Pyrazole, Pyrazolidine, and Phthalazine Derivatives. *J. Org. Chem.* **2006,** *71*, 135-141; (b) Shao, Z.; Chen, J.; Tu, Y.; Li, L.; Zhang, H. A facile aminocyclization for the synthesis of pyrrolidine and piperidine derivatives. *Chem. Commun.* **2003**, 1918-1919.

9. (a) Trost, B. M.; Maulide, N.; Livingston, R. C. A Ruthenium-Catalyzed, Atom-Economical Synthesis of Nitrogen Heterocycles. *J. Am. Chem. Soc.* **2008,** *130*, 16502-16503; (b) Liu, Z.; Hartwig, J. F. Mild, Rhodium-Catalyzed Intramolecular Hydroamination of Unactivated Terminal and Internal Alkenes with Primary and Secondary Amines. *J. Am. Chem. Soc.* **2008,** *130*, 1570-1571; (c) Lu, Z.; Stahl, S. S. Intramolecular Pd(II)-Catalyzed Aerobic Oxidative Amination of Alkenes: Synthesis of Six-Membered N-Heterocycles. *Org. Lett.* **2012,** *14*, 1234-1237; (d) Han, X.; Widenhoefer, R. A. Gold(I)-catalyzed intramolecular hydroamination of alkenyl carbamates. *Angew. Chem. Int. Ed.*, **2006,** *45*, 1747-9.

10. (a) Huang, H. T.; Lacy, T. C.; Blachut, B.; Ortiz, G. X., Jr.; Wang, Q. An efficient synthesis of fluorinated azaheterocycles by aminocyclization of alkenes. *Org Lett* **2013,** *15*, 1818-1821; (b) Wang, Q.; Zhong, W.; Wei, X.; Ning, M.; Meng, X.; Li, Z. Metal-free intramolecular aminofluorination of alkenes mediated by PhI(OPiv)2/hydrogen fluoride-pyridine system. *Org. Biomol. Chem.* **2012,** *10*, 8566-8569; (c) Kong, W.; Feige, P.; de Haro, T.; Nevado, C. Regio- and enantioselective aminofluorination of alkenes. *Angew Chem Int Ed Engl* **2013,** *52*, 2469-73; (d) Teresa, d. H.; Cristina, N. Flexible Gold-Catalyzed Regioselective Oxidative Difunctionalization of Unactivated Alkenes. *Angew. Chem. Int. Ed.* **2011,** *50*, 906-910.

11. (a) Durel, V.; Lalli, C.; Roisnel, T.; van de Weghe, P. Synergistic Effect of the TiCl4/p-TsOH Promoter System on the Aza-Prins Cyclization. *J. Org. Chem.* **2016,** *81*, 849-59; (b) Katamura, T.; Shimizu, T.; Mutoh, Y.; Saito, S. Synthesis of Tricyclic Benzazocines by Aza-Prins Reaction. *Org. Lett.* **2017,** *19*, 266-269; (c) Mahía, A.; Badorrey, R.; Gálvez, J. A.; Díaz-de-Villegas, M. D. Diastereoselective Construction of the 6-Oxa-2-azabicyclo[3.2.1]octane Scaffold from Chiral α -Hydroxyaldehyde Derivatives by the Aza-Prins Reaction. *J. Org. Chem.* **2017,** *82*, 8048-8057; (d) Launay, G. G.; Slawin, A. M. Z.; O'Hagan, D. Prins fluorination cyclisations: Preparation of 4-fluoro-pyran and -piperidine heterocycles. *Beilstein J. Org. Chem.* **2010,** *6*, 41; (e) Yadav, J. S.; Reddy, B. V. S.; Ramesh, K.; Kumar, G. G. K. S. N.; Grée, R. An expeditious synthesis of 4-fluoropiperidines via aza-Prins cyclization. *Tetrahedron Lett.* **2010,** *51*, 1578-1581; (f) Reddy, B. V. S.; Borkar, P.; Chakravarthy, P. P.; Yadav, J. S.; Gree, R. Sc(OTf)3-catalyzed intramolecular aza-Prins cyclization for the synthesis of heterobicycles. *Tetrahedron Lett.* **2010,** *51*, 3412-3416; (g) Clarisse, D.; Pelotier, B.; Fache, F. Solvent-Free, Metal-Free, Aza-Prins Cyclization: Unprecedented Access to δ -Sultams. *Chem. Eur. J.* **2013,** *19*, 857-860; (h) Sun, Y.; Chen, P.; Zhang, D.; Baunach, M.; Hertweck, C.; Li, A. Bioinspired Total Synthesis of Sespenine. *Angew. Chem. Int. Ed.* **2014,** *53*, 9012-9016; (i) Nallasivam, J. L.; Fernandes, R. A. A Cascade Aza-Cope/Aza-Prins Cyclization Leading to Piperidine Derivatives. *Eur. J. Org. Chem.* **2015,** *2015*, 2012-2022; (j) Okoromoba, O. E.; Hammond, G. B.; Xu, B. Preparation of Fluorinated Tetrahydropyrans and Piperidines using a New Nucleophilic Fluorination Reagent DMPU/HF. *Org Lett* **2015,** *17*, 3975-7; (k) Chio, F. K. I.; Guesné, S. J. J.; Hassall, L.; McGuire, T.; Dobbs, A. P. Synthesis of Azabicycles via Cascade Aza-Prins Reactions: Accessing the Indolizidine and Quinolizidine Cores. *J. Org. Chem.* **2015,** *80*, 9868-9880; (l) Ma, D.; Zhong, Z.; Liu, Z.; Zhang, M.; Xu, S.; Xu, D.; Song, D.; Xie, X.; She, X. Protecting-Group-Free Total Synthesis of (−)-Lycopodine via Phosphoric Acid Promoted Alkyne Aza-Prins Cyclization. *Org. Lett.* **2016,** *18*, 4328-4331; (m) Subba Reddy, B. V.; Nair, P. N.; Antony, A.; Lalli, C.; Grée, R. The Aza-Prins Reaction in the Synthesis of Natural Products and Analogues. *Eur. J. Org. Chem.* **2017,** *2017*, 1805-1819.

12. (a) Ebule, R.; Liang, S.; Hammond, G. B.; Xu, B. Chloride-Tolerant Gold(I)-Catalyzed Regioselective Hydrochlorination of Alkynes. *ACS Catal.* **2017,** *7*, 6798-6801; (b) Liang, S.; Ebule, R.; Hammond, G. B.; Xu, B. A Chlorinating Reagent Yields Vinyl Chlorides with High Regioselectivity under Heterogeneous Gold Catalysis. *Org. Lett.* **2017,** *19*, 4524-4527; (c) Zeng, X.; Liu, S.; Hammond, G. B.; Xu, B. Hydrogen-Bonding-Assisted Brønsted Acid and Gold Catalysis: Access to Both (E)- and (Z)-1,2-Haloalkenes via Hydrochlorination of Haloalkynes. *ACS Catal.* **2018,** *8*, 904-909; (d) Zeng, X.; Lu, Z.; Liu, S.; Hammond, G. B.; Xu, B. Metal-free, Regio-, and Stereo-Controlled Hydrochlorination and Hydrobromination of Ynones and Ynamides. *J. Org. Chem.* **2017,** *82*, 13179-13187.

13. (a) Varkey, T. E.; Whitfield, G. F.; Swern, D. Activation of dimethyl sulfoxide by electrophiles and use of the reactive intermediates in the preparation of iminosulfuranes. *J. Org. Chem.* **1974,** *39*, 3365-3372; (b) Mancuso, A. J.; Swern, D. ACTIVATED DIMETHYLSULFOXIDE - USEFUL REAGENTS FOR SYNTHESIS. *Synthesis* **1981**, 165-185.

14. Wu, X.-F.; Natte, K. The Applications of Dimethyl Sulfoxide as Reagent in Organic Synthesis. *Adv. Synth. Catal.* **2016,** *358*, 336-352.

15. (a) Liu, H.; Jiang, X. Transfer of sulfur: from simple to diverse. *Chem Asian J* **2013,** *8*, 2546-63; (b) Sun, K.; Lv, Y.; Zhu, Z.; Zhang, L.; Wu, H.; Liu, L.; Jiang, Y.; Xiao, B.; Wang, X. Oxidative C – S bond cleavage reaction of DMSO for C – N and C – C bond formation: new Mannich-type reaction for β -amino ketones. *RSC Adv.* **2015,** *5*, 3094-3097; (c) Zhang, R.; Shi, X. Q.; Yan, Q. Q.; Li, Z. J.; Wang, Z.; Yu, H. F.; Wang, X. K.; Qi, J.; Jiang, M. L. Free-radical initiated cascade methylation or trideuteromethylation of isocyanides with dimethyl sulfoxides. *RSC Adv.* **2017,** *7*, 38830-38833; (d) Patel, O. P. S.; Anand, D.; Maurya, R. K.; Yadav, P. P. H2O2/DMSO-Promoted Regioselective Synthesis of 3,3'-Bisimidazopyridinylmethanes via Intermolecular Oxidative C(sp(2))-H Bond Activation of Imidazoheterocycles. *J. Org. Chem.* **2016,** *81*, 7626-34; (e) Jadhav, S. D.; Singh, A. Oxidative Annulations Involving DMSO and Formamide: K2S2O8 Mediated Syntheses of Quinolines and Pyrimidines. *Org Lett* **2017,** *19*, 5673-5676; (f) Lv, Y.; Li, Y.; Xiong, T.; Pu, W.; Zhang, H.; Sun, K.; Liu, Q.; Zhang, Q. Copper-catalyzed annulation of amidines for quinazoline synthesis. *Chem. Commun.* **2013,** *49*, 6439-41; (g) Yuan, J.; Yu, J. T.; Jiang, Y.; Cheng, J. Carbon annulation of ortho-vinylanilines with dimethyl sulfoxide to access 4-aryl quinolines. *Org Biomol Chem* **2017,** *15*, 1334-1337.

16. Lu, D.-F.; Liu, G.-S.; Zhu, C.-L.; Yuan, B.; Xu, H. Iron(II)-Catalyzed Intramolecular Olefin Aminofluorination. *Org. Lett.* **2014,** *16*, 2912-2915.

17. Wen, Z.-K.; Liu, X.-H.; Liu, Y.-F.; Chao, J.-B. Acid Promoted Direct Cross-Coupling of Methyl Ketones with Dimethyl Sulfoxide: Access to Ketoallyl Methylsulfides and -sulfones. *Org. Lett.* **2017,** *19*, 5798-5801.

18. Kappe, C. O., Product Class 2: Alkylidenesulfonium Salts or α -Sulfanyl Carbocations. In *Category 4. Compounds with Two Carbon Heteroatom Bonds*, **2005** ed.; Padwa, A.; Bellus, D., Eds. Georg Thieme Verlag: Stuttgart, 2005; Vol. 27.
19. (a) Smith, L. H.; Coote, S. C.; Sneddon, H. F.; Procter, D. J. Beyond the Pummerer reaction: recent developments in thionium ion chemistry. *Angew. Chem. Int. Ed.* **2010,** *49*, 5832-44; (b) Bur, S. K.; Padwa, A. The Pummerer Reaction: Methodology and Strategy for the Synthesis of Heterocyclic Compounds. *Chem. Rev.* **2004,** *104*, 2401-2432; (c) Akai, S.; Kita, Y., Recent Advances in Pummerer Reactions. In *Sulfur-Mediated Rearrangements I*, Schaumann, E., Ed. Springer Berlin Heidelberg: Berlin, Heidelberg, **2007**; pp 35-76.
20. (a) Jiang, X.; Wang, C.; Wei, Y.; Xue, D.; Liu, Z.; Xiao, J. A general method for N-methylation of amines and nitro compounds with dimethylsulfoxide. *Chem. Eur. J.* **2014,** *20*, 58-63; (b) Xue, L.; Cheng, G.; Zhu, R.; Cui, X. Acid-promoted oxidative methylenation of 1,3-dicarbonyl compounds with DMSO: application to the three-component synthesis of Hantzsch-type pyridines. *RSC Advances* **2017,** *7*, 44009-44012.
21. (a) Wu, T.; Yin, G.; Liu, G. Palladium-Catalyzed Intramolecular Aminofluorination of Unactivated Alkenes. *J. Am. Chem. Soc.* **2009,** *131*, 16354-16355; (b) Kong, W.; Feige, P.; de Haro, T.; Nevado, C. Regio- and Enantioselective Aminofluorination of Alkenes. *Angew. Chem. Int. Ed.* **2013,** *52*, 2469-2473; (c) Liu, G.-Q.; Li, Y.-M. Regioselective (Diacetoxyiodo)benzene-Promoted Halocyclization of Unfunctionalized Olefins. *J. Org. Chem.* **2014,** *79*, 10094-10109.
22. Ni, Y.; Zuo, H.; Yu, H.; Wu, Y.; Zhong, F. Synergistic Catalysis-Enabled Thia-Aza-Prins Cyclization with DMSO and Disulfides: Entry to Sulfenylated 1,3-Oxazinanes and Oxazolidines. *Org. Lett.* **2018,** *20*, 5899-5904.
23. Ebule, R.; Hammond, G. B.; Xu, B. Metal-Free Chlorothiolation of Alkenes Using HCl and Sulfoxides. *Eur. J. Org. Chem.* **2018**, 4705-4708.
24. For intramolecular iminium cyclizations see: (a) Memeo, M. G.; Quadrelli, P. Iminium Ions as Dienophiles in Aza-Diels‐Alder Reactions: A Closer Look. *Chem. Eur. J.* **2012,** *18*, 12554-12582; (b) Remuson, R.; Gelas-Mialhe, Y. A Convenient Access to the Piperidine Ring by Cyclization of Allylsilyl Substituted N-acyliminium and Iminium Ions: Application to the Synthesis of Piperidine Alkaloids. *Mini Rev. Org. Chem.* **2008,** *5*, 193-208; (c) Dounay, A. B.; Humphreys, P. G.; Overman, L. E.; Wrobleski, A. D. Total Synthesis of the Strychnos Alkaloid (+)-Minfiensine: Tandem Enantioselective Intramolecular Heck−Iminium Ion Cyclization. *J. Am. Chem. Soc.* **2008,** *130*, 5368-5377; (d) Maryanoff, B. E.; Zhang, H.-C.; Cohen, J. H.; Turchi, I. J.; Maryanoff, C. A. Cyclizations of N-Acyliminium Ions. *Chem. Rev.* **2004,** *104*, 1431-1628; (e) Snider, B. B. Intramolecular cycloaddition reactions of ketenes and keteniminium salts with alkenes. *Chem. Rev.* **1988,** *88*, 793-811; (f) Overman, L. E.; Sharp, M. J. Nucleophile-promoted electrophilic cyclization reactions of alkynes. *J. Am. Chem. Soc.* **1988,** *110*, 612-614.
25. Zheng, J.; Huang, L.; Huang, C.; Wu, W.; Jiang, H. Synthesis of Polysubstituted Pyrroles via Pd-Catalyzed Oxidative Alkene C‐H Bond Arylation and Amination. *J. Org. Chem.* **2015,** *80*, 1235-1242.

TOC


HCl•DMPU
via Pummerer fragmentation
HCl
Moderate to good yields.
Over 30 examples.